fashion -WSS

fashion

author：comprehensive 2025-09-29 19:59:37 - browse：63999

Several amyloid plaques forming between neurons in a brain — Amyloid plaques forming between neurons. Adobe

The Food and Drug Administration on Thursday granted full approval to the first therapy for Alzheimer’s disease clearly shown to slow the cognitive decline associated with the disease — a milestone in treatment, even if the benefits are modest.

The drug, called Leqembi, was developed by Eisai, the Japanese pharmaceutical company, and sold in partnership with Biogen. It previously secured conditional approval in January. The FDA’s decision will broaden patient access to the drug under the Medicare program and is likely to boost sales, even as Leqembi’s benefits and safety risks continue to be a source of debate.

Leqembi’s full, or traditional, approval was supported by results of a large clinical trial in which the drug slowed the rate of cognitive and functional decline by 27% compared to a placebo. Leqembi also beat placebo on a series of secondary measures of Alzheimer’s, and it had a dramatic effect on clearing toxic brain plaques called beta-amyloid, which play a role in the progression of the disease.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： STAT Readout: Friday, Oct. 20 biotech updates

hotspot

WSS

STAT Summit: Ending the crisis of Black deaths in the U.S.

Cardiologists urge adding sexual orientation, gender identity to health records

Flu vaccine reformulation won't be easy, manufacturers warn

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

UnitedHealth, Optum discontinue NaviHealth name

The problems with dementia villages

knowledge

fashion

focus

Medical leaders decry Supreme Court decision on affirmative action

Microsoft launches AI tool for clinical documentation through Epic

Virginia high school admissions case could be legal follow

STAT Summit: The economic case for universal basic health care

What does generative AI mean for health care? We asked experts

A pediatrician calls for Congress to pass the child tax credit deal

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

FDA sets aggressive timeline for overhauling inspection procedures

focus

Medicare bonuses could stop drug shortages under Senate plan

Future doctors need a strong humanities education

Smaller biotechs seek to piggyback on weight loss drug boom

ADCs take center stage as promising cancer treatments

CVS is on a mission to consolidate health care. Will it work?

Prior authorization reform is both possible and imperative

hotspot

leisure time

leisure time

explore